Form4insider filings, from the source

SEC Form 4 · accession 0001179110-17-009109

Assertio Therapeutics, Inc · ASRT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Thadd M Vargas
Officer — SVP, Business Development
Period of report
Jun 13, 2017
Accepted (ET)
Jun 15, 2017 · 4:43 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001005201

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF2,F1Jun 13, 2017S21,751$9.587D19,816D
Common StockF2,F1Jun 13, 2017S19,816$9.60D0D
Common StockF1Jun 13, 2017M19,320$7.12A19,320D
Common StockF1Jun 13, 2017M45,000$6.08A64,320D
Common StockF1Jun 13, 2017M43,000$6.11A107,320D
Common StockF1Jun 13, 2017M53,500$6.77A160,820D
Common StockF2,F1Jun 13, 2017S160,820$9.526D0D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Common StockF3$7.12Jun 13, 2017M19,320D—Jan 14, 2021Common Stock19,3200D
Common StockF4$6.08Jun 13, 2017M45,000D—Sep 1, 2021Common Stock45,0000D
Common StockF5$6.11Jun 13, 2017M43,000D—Jan 12, 2022Common Stock43,0000D
Common StockF6$6.77Jun 13, 2017M53,500D—Feb 7, 2023Common Stock53,5000D

Explanation of responses